UNSPSC 51142500: Antiparkinson drugs

This classification denotes drugs that treat a progressive, degenerative neurologic disease, called parkinson's disease, characterized by a tremor that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem.

UNSPSC 51142500 Antiparkinson drugs is a Class code under which state and local governments procure pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter medications, often through cooperative purchasing arrangements or direct-to-manufacturer programs. Recent solicitations reveal that state and local issuers are primarily focused on acquiring drugs through established distribution channels (authorized wholesalers), securing direct-to-manufacturer prescription programs to bypass traditional pharmacy benefit managers, and procuring emergency medical countermeasures like naloxone for public health initiatives. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local facilities across participating jurisdictions including Oregon). The code reflects a mix of emergency preparedness procurement, routine pharmaceutical supply agreements, and innovative contracting models designed to improve cost management and operational efficiency.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with recent opportunities reflecting both single-jurisdiction and multi-state cooperative purchasing frameworks. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for self-insured employee group health plans and state agencies, exploring alternatives to traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and awards effective July 1, 2026.